The present invention concerns ophthalmic compositions comprising a combination of hyaluronic acid (HA) as a vehicle, and one or more prostaglandin analogues, such as latanoprost, as an active pharmaceutical ingredient (API), wherein the HA acts as a transporting vehicle (transporter) of the prostaglandin analogue into the eye. The invention also includes methods for the use of such ophthalmic compositions for reduction of intraocular pressure to treat, prevent, and/or delay the onset or recurrence of ocular hypertension and glaucoma. The ophthalmic compositions of the invention have improved stability, improved API solubility, and improved efficacy in reducing intraocular pressure.

The present disclosure relates to an oral eliglustat transmucosal delivery system. More specifically, the present disclosure is related to an oral transmucosal dosage form comprising a non-disintegrating solid mass comprising (a) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (b) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons and (c) not more than 70 mg eliglustat, wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes, and wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec share rate. The dosage forms of as described herein have at least 30% dose reduction as compared to commercially available eliglustat capsules. In addition, unlike the dosing prerequisite for commercially available eliglustat capsules, the oral eliglustat transmucosal dosage form described herein can be administered to patients with Gaucher disease type 1 without pre-determination of patients' CYP2D6 genotype.

A hydrate promoter contains a component A which is a substance having a group represented by the Formula I below and a surfactant. A molar ratio of the component A to the surfactant is 1:(0.03-30). The hydrate overcomes the disadvantages of the conventional hydrate promoter, such as small gas storage capacity and low generation rate, the present disclosure is further capable of suppressing generation of air bubbles and improving the gas recovery rate of hydrate during decomposition process of the hydrate, as compared to the conventional hydrate promoter, thus has a favorable application prospect for natural gas storage and transportation with the hydrate.

##STR00001##

A hydrate promoter contains a component A which is a substance having a group represented by the Formula I below and a surfactant. A molar ratio of the component A to the surfactant is 1:(0.03-30). The hydrate overcomes the disadvantages of the conventional hydrate promoter, such as small gas storage capacity and low generation rate, the present disclosure is further capable of suppressing generation of air bubbles and improving the gas recovery rate of hydrate during decomposition process of the hydrate, as compared to the conventional hydrate promoter, thus has a favorable application prospect for natural gas storage and transportation with the hydrate.

##STR00001##

The present invention relates to a pharmaceutical composition for prevention or treatment of coronavirus infections, comprising a delayed-release composition of niclosamide or a pharmaceutically acceptable salt thereof, and a method for preventing or treating coronavirus infections by using the same.

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.

In some aspects, the present disclosure provides pharmaceutical compositions comprising a) a therapeutic agent; b) a metal-organic framework (MOF) or a coordination polymer; and c) a pharmaceutically acceptable polymer; wherein the therapeutic agent is encapsulated within the metal-organic framework or coordination polymer to form an encapsulated therapeutic agent, and wherein the encapsulated therapeutic agent is further encapsulated, entrapped, embedded, dispersed within, or complexed to the pharmaceutically acceptable polymer. The present disclosure also provides methods of making said compositions, methods of treating a disease or disorder comprising administering to a subject said compositions. The present disclosure also provides microneedles and implantable medical devices comprising said compositions.

Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.

Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.

The present invention relates to a homogeneous composition comprising a steroid compound and olopatadine, wherein the steroid compound is in a stable suspension state, and the olopatadine is in a stable solution state, and a process thereof.